The FDA is developing a new framework for flu vaccines aimed at addressing challenges with strain selection and efficacy variability year-to-year. Meanwhile, multiple insurers reduce or withdraw earnings guidance citing individual market dynamics that impact profitability. Calidi Biotherapeutics announces a 1-for-12 reverse stock split to consolidate shares ahead of anticipated market movements. Industry leaders also call for continuation of remote prescribing of controlled substances to sustain telemedicine innovations.